Clinical Trial Update: A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 study of the CDK4/6 inhibitor palbociclib in patients with advanced cancer, including Non-Hodgkin lymphoma, has completed and posted results in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Pfizer | Conditions: Neoplasms, Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED | Results posted: 2015-10-28